What you should know:
1. RedHill and Salix entered into a licensing agreement in 2014 for the therapy, which is now in development.
2. The pill is a flavorless, solid oral preparation that eases patient burden and improves the likelihood of a successful outcome.
3. Researchers recently completed a phase 2A study of a past version of the pill, which concluded with 62 patients demonstrating comparable bowel preparation to traditional preparation solutions.
4. RedHill CEO Dror Ben-Asher said the reacquisition of RHB-106 aligned with the company’s commercial activities in the U.S.
More articles on surgery centers:
Supply chain tip of the week: Grow your ASC sustainably
How ASCs purchase devices, equipment: 3 insights
Supply chain tip of the week: Streamline supply consumption
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
